Compare Freshworks Inc (FRSH) vs Hims and Hers Health Inc (HIMS) Price & Performance

Freshworks (FRSH) trades at $13.60, down 1.16% on the day, with a bullish technical outlook from moving averages. The company reported strong Q2 2026 results, beating earnings estimates with EPS of $0.17 versus $0.13 expected, and achieved its first quarter of GAAP profitability. Revenue growth remains robust at 16% year-over-year, supported by strength in its employee experience portfolio and AI adoption.

The investment outlook is positive, driven by sustained revenue growth, improving profitability, and a favorable analyst consensus with a $14.60 price target. Key risks include high valuation multiples like a 43.89 EV/EBITDA and competitive pressures in the SaaS sector. The stock presents an opportunity for rerating if profitability trends continue.

Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.

The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.